Abstract 2978
Background
Cancer and diabetes are prevalent diseases worldwide. The purpose of this study was to assess quality of life and the factors influence it in the individuals with coexistence diabetes type 2 and cancer.
Methods
A cross-sectional study was conducted in a large hospital in a major Greek city. Convenience sample of 101 patients with cancer and diabetes type 2 undergoing chemotherapy constituted the study group. Quality of life was measured by the Audit of Diabetes Depedent-QoL-Questionnaire (ADDQoL-19). Information on social-demographic, treatment of tumors and diabetes, and other clinical characteristics were collected by other questionnaire. Descriptive statistics were used for demographic characteristics. For data that were not normally distributed, nonparametric tests (Mann-Whitney U test, Kruskal-Wallis test) were applied.
Results
The majority of patients had cancer stage II (n = 52, 51,5%) and diabetes 2 for almost seven years. Individuals with coexistence of diabetes 2 and cancer reported that disease affected the overall quality of life (1.84±1.18). Also, there is a negative score in other subscale as freedom to eat (-1.43 ±0.80) and financial situation (-1.25±0,84). It was found that cancer’s stage influences the general quality of life domain (p = 0.023). Also, there were statistical significant differences between type of regimen for diabetes and several domains of quality of life. More particular, working life (p = 0.004), family life (p = 0.003), friendship and social life (p = 0.005), physical health (p = 0.003), leisure activities (p = 0.004) and financial situation (p = 0.004) are some of these domains that they are further influenced. Additionally the family status influences self-confidence (p = 0.001) and motivation (p = 0.007).
Conclusions
Taking all the above under consideration, we conclude that social-demographic and clinical characteristics were associated with quality of life in patients with cancer and diabetes 2.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
4600 - Patterns and outcomes related to rapid progressive disease in a cohort of advanced solid tumors treated with immune checkpoint inhibitors (ICIs).
Presenter: Lucio Ghiglione
Session: Poster Display session 3
Resources:
Abstract
3547 - Real World Outcomes of Immune-Related Adverse Events (irAEs) among Patients Receiving Immune Checkpoint Inhibitors (ICIs) in Hospital Settings
Presenter: Saby George
Session: Poster Display session 3
Resources:
Abstract
1124 - Sex-based heterogeneity of efficacy of anticancer immunotherapy
Presenter: Fabio Conforti
Session: Poster Display session 3
Resources:
Abstract
4133 - Comparative efficacy and safety of PD-1/PD-L1 inhibitors for patients with solid tumors: a systematic review and Bayesian network meta-analysis
Presenter: Qingyuan Huang
Session: Poster Display session 3
Resources:
Abstract
2548 - Excess weight and efficacy of anti-PD-1 antibodies in advanced cancer patients
Presenter: Jacobo Rogado
Session: Poster Display session 3
Resources:
Abstract
2228 - Safety and efficacy of anti-PD-1 inhibitor ABBV-181 in lung and head and neck carcinoma
Presenter: Antoine Italiano
Session: Poster Display session 3
Resources:
Abstract
2333 - Efficacy and safety of immune checkpoint inhibitors (ICIs) for treatment of advanced solid tumours in octogenarian patients
Presenter: Soraya Mebarki
Session: Poster Display session 3
Resources:
Abstract
4847 - Association of programmed cell death 1 (PD-1) inhibitor therapy with overall survival (OS) in stage IV melanoma treated with targeted therapies
Presenter: Aracelis Torres
Session: Poster Display session 3
Resources:
Abstract
2215 - Clinical outcomes of immune checkpoint inhibitors in older and younger patients with advanced solid tumours in a real-life setting
Presenter: Pauline Corbaux
Session: Poster Display session 3
Resources:
Abstract
2881 - Impact of corticosteroids and antibiotics on efficacy of immune-checkpoint inhibitors in advanced non-small cell lung cancer
Presenter: Joaquin Mosquera Martinez
Session: Poster Display session 3
Resources:
Abstract